Brokerages expect that Heron Therapeutics, Inc. (NASDAQ:HRTX) will report $4.53 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Heron Therapeutics’ earnings. The lowest sales estimate is $4.36 million and the highest is $4.70 million. The firm is expected to announce its next quarterly earnings report on Monday, August 14th.

On average, analysts expect that Heron Therapeutics will report full year sales of $4.53 million for the current year, with estimates ranging from $21.02 million to $22.90 million. For the next fiscal year, analysts expect that the firm will post sales of $83.90 million per share. Zacks’ sales averages are an average based on a survey of analysts that follow Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.94) by $0.06. The company had revenue of $3.63 million for the quarter, compared to the consensus estimate of $1.96 million.

Several equities analysts have issued reports on the company. Jefferies Group LLC reiterated a “buy” rating and issued a $26.00 target price on shares of Heron Therapeutics in a research note on Friday, July 14th. Zacks Investment Research lowered Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 9th. Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Friday, May 12th. Aegis restated a “buy” rating and set a $33.00 price target on shares of Heron Therapeutics in a research note on Tuesday. Finally, ValuEngine upgraded Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating and eleven have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $31.00.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Anticipate Heron Therapeutics, Inc. (HRTX) Will Post Quarterly Sales of $4.53 Million” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/20/zacks-analysts-anticipate-heron-therapeutics-inc-hrtx-will-post-quarterly-sales-of-4-53-million.html.

Shares of Heron Therapeutics (NASDAQ HRTX) traded up 3.061% during trading on Thursday, reaching $17.675. 703,961 shares of the company were exchanged. Heron Therapeutics has a 1-year low of $12.21 and a 1-year high of $24.00. The firm’s 50 day moving average is $14.34 and its 200 day moving average is $14.21.

In other Heron Therapeutics news, VP Kimberly Manhard sold 21,542 shares of the business’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $15.33, for a total value of $330,238.86. Following the completion of the transaction, the vice president now directly owns 5,250 shares of the company’s stock, valued at $80,482.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 20.31% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in HRTX. Swiss National Bank boosted its stake in Heron Therapeutics by 39.9% in the first quarter. Swiss National Bank now owns 72,600 shares of the biotechnology company’s stock worth $1,089,000 after buying an additional 20,700 shares during the period. Bank of New York Mellon Corp boosted its stake in Heron Therapeutics by 27.1% in the first quarter. Bank of New York Mellon Corp now owns 190,771 shares of the biotechnology company’s stock worth $2,861,000 after buying an additional 40,657 shares during the period. Falcon Point Capital LLC acquired a new stake in Heron Therapeutics during the first quarter worth approximately $501,000. Searle & CO. acquired a new stake in Heron Therapeutics during the first quarter worth approximately $353,000. Finally, Wells Fargo & Company MN boosted its stake in Heron Therapeutics by 78.8% in the first quarter. Wells Fargo & Company MN now owns 39,579 shares of the biotechnology company’s stock worth $595,000 after buying an additional 17,442 shares during the period.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.